L&C Bio Balance Sheet Health
Financial Health criteria checks 3/6
L&C Bio has a total shareholder equity of ₩156.9B and total debt of ₩79.9B, which brings its debt-to-equity ratio to 50.9%. Its total assets and total liabilities are ₩262.2B and ₩105.4B respectively. L&C Bio's EBIT is ₩7.7B making its interest coverage ratio 1.7. It has cash and short-term investments of ₩59.2B.
Key information
50.9%
Debt to equity ratio
₩79.86b
Debt
| Interest coverage ratio | 1.7x |
| Cash | ₩59.19b |
| Equity | ₩156.86b |
| Total liabilities | ₩105.37b |
| Total assets | ₩262.23b |
Recent financial health updates
Recent updates
L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions
Mar 27
Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?
Apr 20L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality
Apr 01Is L&C Bio (KOSDAQ:290650) A Risky Investment?
Mar 02Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year
Feb 03What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?
Jan 04Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?
Dec 08Financial Position Analysis
Short Term Liabilities: A290650's short term assets (₩130.4B) exceed its short term liabilities (₩101.8B).
Long Term Liabilities: A290650's short term assets (₩130.4B) exceed its long term liabilities (₩3.5B).
Debt to Equity History and Analysis
Debt Level: A290650's net debt to equity ratio (13.2%) is considered satisfactory.
Reducing Debt: A290650's debt to equity ratio has increased from 1.9% to 50.9% over the past 5 years.
Debt Coverage: A290650's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A290650's interest payments on its debt are not well covered by EBIT (1.7x coverage).